Loading…

Proteomic detection of a large amount of SCGFα in the stroma of GISTs after imatinib therapy

Gastrointestinal stromal tumors (GISTs) are the most frequent mesenchymal tumors to develop in the digestive tract. These tumors are highly resistant to conventional chemotherapy and only the introduction of imatinib mesylate has improved the prognosis of patients. However, Response Evaluation Crite...

Full description

Saved in:
Bibliographic Details
Published in:Journal of translational medicine 2011-09, Vol.9 (1), p.158-158, Article 158
Main Authors: Da Riva, Luca, Bozzi, Fabio, Mondellini, Piera, Miccichè, Francesca, Fumagalli, Elena, Vaghi, Elena, Tarantino, Eva, Huber, Veronica, Gronchi, Alessandro, Tamborini, Elena, Pierotti, Marco A, Pilotti, Silvana, Bongarzone, Italia
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-b517t-8cd06f72cda6ea5abad1092f0148d8fdef77ca57d52dc064c9471d80045962e63
cites cdi_FETCH-LOGICAL-b517t-8cd06f72cda6ea5abad1092f0148d8fdef77ca57d52dc064c9471d80045962e63
container_end_page 158
container_issue 1
container_start_page 158
container_title Journal of translational medicine
container_volume 9
creator Da Riva, Luca
Bozzi, Fabio
Mondellini, Piera
Miccichè, Francesca
Fumagalli, Elena
Vaghi, Elena
Tarantino, Eva
Huber, Veronica
Gronchi, Alessandro
Tamborini, Elena
Pierotti, Marco A
Pilotti, Silvana
Bongarzone, Italia
description Gastrointestinal stromal tumors (GISTs) are the most frequent mesenchymal tumors to develop in the digestive tract. These tumors are highly resistant to conventional chemotherapy and only the introduction of imatinib mesylate has improved the prognosis of patients. However, Response Evaluation Criteria in Solid Tumors are inappropriate for assessing tumor response, and the histological/pathological response to imatinib is variable, heterogeneous, and does not associate with clinical response. The effects of imatinib on responding GISTs are still being explored, and few studies correlate the clinical response with the histological response after pharmacological treatment. Recently, apoptosis and autophagy were suggested as possible alternative mechanisms of pharmacological response. Here, we used a proteomic approach, combined with other analyses, to identify some molecular stromal components related to the response/behavior of resected, high-risk GISTs after neoadiuvant imatinib therapy. Our proteomic results indicate an elevated concentration of Stem Cell Growth Factor (SCGF), a hematopoietic growth factor having a role in the development of erythroid and myeloid progenitors, in imatinib-responsive tumor areas. SCGFα expression was detected by mass spectrometry, immunohistochemistry and/or western blot and attributed to acellular matrix of areas scored negative for KIT (CD117). RT-PCR results indicated that GIST samples did not express SCGF transcripts. The recently reported demonstration by Gundacker et al. 1 of the secretion of SCGF in mature pro-inflammatory dendritic cells would indicate a potential importance of SCGF in tissue inflammatory response. Accordingly, inflammatory infiltrates were detected in imatinib-affected areas and the CD68-positivity of the SCGF-positive and KIT-negative areas suggested previous infiltration of monocytes/macrophages into these regions. Thus, chronic inflammation subsequent to imatinib treatment may determine monocyte/macrophage recruitment in imatinib-damaged areas; these areas also feature prominent tumor-cell loss that is replaced by dense hyalinization and fibrosis. Our studies highlight a possible role of SCGFα in imatinib-induced changes of GIST structure, consistent with a therapeutic response.
doi_str_mv 10.1186/1479-5876-9-158
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_aebd56ac1997413d8dbbbc60c6042c04</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_aebd56ac1997413d8dbbbc60c6042c04</doaj_id><sourcerecordid>898500939</sourcerecordid><originalsourceid>FETCH-LOGICAL-b517t-8cd06f72cda6ea5abad1092f0148d8fdef77ca57d52dc064c9471d80045962e63</originalsourceid><addsrcrecordid>eNp1kl1rFDEUhgex2Fq99k5y59XYZCafN4Iudl0oWGh7KeHkY7YpM5M1yRb6s_wj_iZn3Lp0wUIg4T0vzznhPVX1juCPhEh-RqhQNZOC16omTL6oTvbKyyfv4-p1zncYN5RR9ao6boiiLWnUSfXjMsXi4xAscr54W0IcUewQoB7S2iMY4nYss3K1WJ7__oXCiMqtR7mkOMCsL1dX1xlBV3xCYYASxmBmS4LNw5vqqIM--7eP92l1c_71evGtvvi-XC0-X9SGEVFqaR3mnWisA-6BgQFHsGo6TKh0snO-E8ICE441zmJOraKCOIkxZYo3nren1WrHdRHu9CZNc6QHHSHov0JMaw2pBNt7Dd44xsESpQQlrZPOGGM5ng5tLKYT69OOtdmawTvrx5KgP4AeVsZwq9fxXrdENVy2E-DLDmBCfAZwWLFx0HNUeo5KKz0FOUE-PE6R4s-tz0UPIVvf9zD6uM1aKskwVq2anGc7p00x5-S7fSeC9bwk_2G_f_rDvf_fVrR_AJ5ZueE</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>898500939</pqid></control><display><type>article</type><title>Proteomic detection of a large amount of SCGFα in the stroma of GISTs after imatinib therapy</title><source>Publicly Available Content Database</source><source>PubMed Central(OpenAccess)</source><creator>Da Riva, Luca ; Bozzi, Fabio ; Mondellini, Piera ; Miccichè, Francesca ; Fumagalli, Elena ; Vaghi, Elena ; Tarantino, Eva ; Huber, Veronica ; Gronchi, Alessandro ; Tamborini, Elena ; Pierotti, Marco A ; Pilotti, Silvana ; Bongarzone, Italia</creator><creatorcontrib>Da Riva, Luca ; Bozzi, Fabio ; Mondellini, Piera ; Miccichè, Francesca ; Fumagalli, Elena ; Vaghi, Elena ; Tarantino, Eva ; Huber, Veronica ; Gronchi, Alessandro ; Tamborini, Elena ; Pierotti, Marco A ; Pilotti, Silvana ; Bongarzone, Italia</creatorcontrib><description>Gastrointestinal stromal tumors (GISTs) are the most frequent mesenchymal tumors to develop in the digestive tract. These tumors are highly resistant to conventional chemotherapy and only the introduction of imatinib mesylate has improved the prognosis of patients. However, Response Evaluation Criteria in Solid Tumors are inappropriate for assessing tumor response, and the histological/pathological response to imatinib is variable, heterogeneous, and does not associate with clinical response. The effects of imatinib on responding GISTs are still being explored, and few studies correlate the clinical response with the histological response after pharmacological treatment. Recently, apoptosis and autophagy were suggested as possible alternative mechanisms of pharmacological response. Here, we used a proteomic approach, combined with other analyses, to identify some molecular stromal components related to the response/behavior of resected, high-risk GISTs after neoadiuvant imatinib therapy. Our proteomic results indicate an elevated concentration of Stem Cell Growth Factor (SCGF), a hematopoietic growth factor having a role in the development of erythroid and myeloid progenitors, in imatinib-responsive tumor areas. SCGFα expression was detected by mass spectrometry, immunohistochemistry and/or western blot and attributed to acellular matrix of areas scored negative for KIT (CD117). RT-PCR results indicated that GIST samples did not express SCGF transcripts. The recently reported demonstration by Gundacker et al. 1 of the secretion of SCGF in mature pro-inflammatory dendritic cells would indicate a potential importance of SCGF in tissue inflammatory response. Accordingly, inflammatory infiltrates were detected in imatinib-affected areas and the CD68-positivity of the SCGF-positive and KIT-negative areas suggested previous infiltration of monocytes/macrophages into these regions. Thus, chronic inflammation subsequent to imatinib treatment may determine monocyte/macrophage recruitment in imatinib-damaged areas; these areas also feature prominent tumor-cell loss that is replaced by dense hyalinization and fibrosis. Our studies highlight a possible role of SCGFα in imatinib-induced changes of GIST structure, consistent with a therapeutic response.</description><identifier>ISSN: 1479-5876</identifier><identifier>EISSN: 1479-5876</identifier><identifier>DOI: 10.1186/1479-5876-9-158</identifier><identifier>PMID: 21943129</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Benzamides ; Blotting, Western ; Cell Line, Tumor ; Electrophoresis, Polyacrylamide Gel ; Gastrointestinal Stromal Tumors - drug therapy ; Gastrointestinal Stromal Tumors - genetics ; Gastrointestinal Stromal Tumors - metabolism ; Gastrointestinal Stromal Tumors - pathology ; Gene Expression Regulation, Neoplastic ; Glycosylation ; Hematopoietic Cell Growth Factors - genetics ; Hematopoietic Cell Growth Factors - metabolism ; Humans ; Imatinib Mesylate ; Immunohistochemistry ; Lectins, C-Type - genetics ; Lectins, C-Type - metabolism ; Piperazines - therapeutic use ; Proteomics - methods ; Pyrimidines - therapeutic use ; RNA, Messenger - genetics ; RNA, Messenger - metabolism ; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization ; Stromal Cells - metabolism ; Stromal Cells - pathology</subject><ispartof>Journal of translational medicine, 2011-09, Vol.9 (1), p.158-158, Article 158</ispartof><rights>Copyright ©2011 Da Riva et al; licensee BioMed Central Ltd. 2011 Da Riva et al; licensee BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b517t-8cd06f72cda6ea5abad1092f0148d8fdef77ca57d52dc064c9471d80045962e63</citedby><cites>FETCH-LOGICAL-b517t-8cd06f72cda6ea5abad1092f0148d8fdef77ca57d52dc064c9471d80045962e63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3192683/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3192683/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,37013,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21943129$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Da Riva, Luca</creatorcontrib><creatorcontrib>Bozzi, Fabio</creatorcontrib><creatorcontrib>Mondellini, Piera</creatorcontrib><creatorcontrib>Miccichè, Francesca</creatorcontrib><creatorcontrib>Fumagalli, Elena</creatorcontrib><creatorcontrib>Vaghi, Elena</creatorcontrib><creatorcontrib>Tarantino, Eva</creatorcontrib><creatorcontrib>Huber, Veronica</creatorcontrib><creatorcontrib>Gronchi, Alessandro</creatorcontrib><creatorcontrib>Tamborini, Elena</creatorcontrib><creatorcontrib>Pierotti, Marco A</creatorcontrib><creatorcontrib>Pilotti, Silvana</creatorcontrib><creatorcontrib>Bongarzone, Italia</creatorcontrib><title>Proteomic detection of a large amount of SCGFα in the stroma of GISTs after imatinib therapy</title><title>Journal of translational medicine</title><addtitle>J Transl Med</addtitle><description>Gastrointestinal stromal tumors (GISTs) are the most frequent mesenchymal tumors to develop in the digestive tract. These tumors are highly resistant to conventional chemotherapy and only the introduction of imatinib mesylate has improved the prognosis of patients. However, Response Evaluation Criteria in Solid Tumors are inappropriate for assessing tumor response, and the histological/pathological response to imatinib is variable, heterogeneous, and does not associate with clinical response. The effects of imatinib on responding GISTs are still being explored, and few studies correlate the clinical response with the histological response after pharmacological treatment. Recently, apoptosis and autophagy were suggested as possible alternative mechanisms of pharmacological response. Here, we used a proteomic approach, combined with other analyses, to identify some molecular stromal components related to the response/behavior of resected, high-risk GISTs after neoadiuvant imatinib therapy. Our proteomic results indicate an elevated concentration of Stem Cell Growth Factor (SCGF), a hematopoietic growth factor having a role in the development of erythroid and myeloid progenitors, in imatinib-responsive tumor areas. SCGFα expression was detected by mass spectrometry, immunohistochemistry and/or western blot and attributed to acellular matrix of areas scored negative for KIT (CD117). RT-PCR results indicated that GIST samples did not express SCGF transcripts. The recently reported demonstration by Gundacker et al. 1 of the secretion of SCGF in mature pro-inflammatory dendritic cells would indicate a potential importance of SCGF in tissue inflammatory response. Accordingly, inflammatory infiltrates were detected in imatinib-affected areas and the CD68-positivity of the SCGF-positive and KIT-negative areas suggested previous infiltration of monocytes/macrophages into these regions. Thus, chronic inflammation subsequent to imatinib treatment may determine monocyte/macrophage recruitment in imatinib-damaged areas; these areas also feature prominent tumor-cell loss that is replaced by dense hyalinization and fibrosis. Our studies highlight a possible role of SCGFα in imatinib-induced changes of GIST structure, consistent with a therapeutic response.</description><subject>Benzamides</subject><subject>Blotting, Western</subject><subject>Cell Line, Tumor</subject><subject>Electrophoresis, Polyacrylamide Gel</subject><subject>Gastrointestinal Stromal Tumors - drug therapy</subject><subject>Gastrointestinal Stromal Tumors - genetics</subject><subject>Gastrointestinal Stromal Tumors - metabolism</subject><subject>Gastrointestinal Stromal Tumors - pathology</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Glycosylation</subject><subject>Hematopoietic Cell Growth Factors - genetics</subject><subject>Hematopoietic Cell Growth Factors - metabolism</subject><subject>Humans</subject><subject>Imatinib Mesylate</subject><subject>Immunohistochemistry</subject><subject>Lectins, C-Type - genetics</subject><subject>Lectins, C-Type - metabolism</subject><subject>Piperazines - therapeutic use</subject><subject>Proteomics - methods</subject><subject>Pyrimidines - therapeutic use</subject><subject>RNA, Messenger - genetics</subject><subject>RNA, Messenger - metabolism</subject><subject>Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</subject><subject>Stromal Cells - metabolism</subject><subject>Stromal Cells - pathology</subject><issn>1479-5876</issn><issn>1479-5876</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNp1kl1rFDEUhgex2Fq99k5y59XYZCafN4Iudl0oWGh7KeHkY7YpM5M1yRb6s_wj_iZn3Lp0wUIg4T0vzznhPVX1juCPhEh-RqhQNZOC16omTL6oTvbKyyfv4-p1zncYN5RR9ao6boiiLWnUSfXjMsXi4xAscr54W0IcUewQoB7S2iMY4nYss3K1WJ7__oXCiMqtR7mkOMCsL1dX1xlBV3xCYYASxmBmS4LNw5vqqIM--7eP92l1c_71evGtvvi-XC0-X9SGEVFqaR3mnWisA-6BgQFHsGo6TKh0snO-E8ICE441zmJOraKCOIkxZYo3nren1WrHdRHu9CZNc6QHHSHov0JMaw2pBNt7Dd44xsESpQQlrZPOGGM5ng5tLKYT69OOtdmawTvrx5KgP4AeVsZwq9fxXrdENVy2E-DLDmBCfAZwWLFx0HNUeo5KKz0FOUE-PE6R4s-tz0UPIVvf9zD6uM1aKskwVq2anGc7p00x5-S7fSeC9bwk_2G_f_rDvf_fVrR_AJ5ZueE</recordid><startdate>20110923</startdate><enddate>20110923</enddate><creator>Da Riva, Luca</creator><creator>Bozzi, Fabio</creator><creator>Mondellini, Piera</creator><creator>Miccichè, Francesca</creator><creator>Fumagalli, Elena</creator><creator>Vaghi, Elena</creator><creator>Tarantino, Eva</creator><creator>Huber, Veronica</creator><creator>Gronchi, Alessandro</creator><creator>Tamborini, Elena</creator><creator>Pierotti, Marco A</creator><creator>Pilotti, Silvana</creator><creator>Bongarzone, Italia</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20110923</creationdate><title>Proteomic detection of a large amount of SCGFα in the stroma of GISTs after imatinib therapy</title><author>Da Riva, Luca ; Bozzi, Fabio ; Mondellini, Piera ; Miccichè, Francesca ; Fumagalli, Elena ; Vaghi, Elena ; Tarantino, Eva ; Huber, Veronica ; Gronchi, Alessandro ; Tamborini, Elena ; Pierotti, Marco A ; Pilotti, Silvana ; Bongarzone, Italia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b517t-8cd06f72cda6ea5abad1092f0148d8fdef77ca57d52dc064c9471d80045962e63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Benzamides</topic><topic>Blotting, Western</topic><topic>Cell Line, Tumor</topic><topic>Electrophoresis, Polyacrylamide Gel</topic><topic>Gastrointestinal Stromal Tumors - drug therapy</topic><topic>Gastrointestinal Stromal Tumors - genetics</topic><topic>Gastrointestinal Stromal Tumors - metabolism</topic><topic>Gastrointestinal Stromal Tumors - pathology</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Glycosylation</topic><topic>Hematopoietic Cell Growth Factors - genetics</topic><topic>Hematopoietic Cell Growth Factors - metabolism</topic><topic>Humans</topic><topic>Imatinib Mesylate</topic><topic>Immunohistochemistry</topic><topic>Lectins, C-Type - genetics</topic><topic>Lectins, C-Type - metabolism</topic><topic>Piperazines - therapeutic use</topic><topic>Proteomics - methods</topic><topic>Pyrimidines - therapeutic use</topic><topic>RNA, Messenger - genetics</topic><topic>RNA, Messenger - metabolism</topic><topic>Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</topic><topic>Stromal Cells - metabolism</topic><topic>Stromal Cells - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Da Riva, Luca</creatorcontrib><creatorcontrib>Bozzi, Fabio</creatorcontrib><creatorcontrib>Mondellini, Piera</creatorcontrib><creatorcontrib>Miccichè, Francesca</creatorcontrib><creatorcontrib>Fumagalli, Elena</creatorcontrib><creatorcontrib>Vaghi, Elena</creatorcontrib><creatorcontrib>Tarantino, Eva</creatorcontrib><creatorcontrib>Huber, Veronica</creatorcontrib><creatorcontrib>Gronchi, Alessandro</creatorcontrib><creatorcontrib>Tamborini, Elena</creatorcontrib><creatorcontrib>Pierotti, Marco A</creatorcontrib><creatorcontrib>Pilotti, Silvana</creatorcontrib><creatorcontrib>Bongarzone, Italia</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Journal of translational medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Da Riva, Luca</au><au>Bozzi, Fabio</au><au>Mondellini, Piera</au><au>Miccichè, Francesca</au><au>Fumagalli, Elena</au><au>Vaghi, Elena</au><au>Tarantino, Eva</au><au>Huber, Veronica</au><au>Gronchi, Alessandro</au><au>Tamborini, Elena</au><au>Pierotti, Marco A</au><au>Pilotti, Silvana</au><au>Bongarzone, Italia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Proteomic detection of a large amount of SCGFα in the stroma of GISTs after imatinib therapy</atitle><jtitle>Journal of translational medicine</jtitle><addtitle>J Transl Med</addtitle><date>2011-09-23</date><risdate>2011</risdate><volume>9</volume><issue>1</issue><spage>158</spage><epage>158</epage><pages>158-158</pages><artnum>158</artnum><issn>1479-5876</issn><eissn>1479-5876</eissn><abstract>Gastrointestinal stromal tumors (GISTs) are the most frequent mesenchymal tumors to develop in the digestive tract. These tumors are highly resistant to conventional chemotherapy and only the introduction of imatinib mesylate has improved the prognosis of patients. However, Response Evaluation Criteria in Solid Tumors are inappropriate for assessing tumor response, and the histological/pathological response to imatinib is variable, heterogeneous, and does not associate with clinical response. The effects of imatinib on responding GISTs are still being explored, and few studies correlate the clinical response with the histological response after pharmacological treatment. Recently, apoptosis and autophagy were suggested as possible alternative mechanisms of pharmacological response. Here, we used a proteomic approach, combined with other analyses, to identify some molecular stromal components related to the response/behavior of resected, high-risk GISTs after neoadiuvant imatinib therapy. Our proteomic results indicate an elevated concentration of Stem Cell Growth Factor (SCGF), a hematopoietic growth factor having a role in the development of erythroid and myeloid progenitors, in imatinib-responsive tumor areas. SCGFα expression was detected by mass spectrometry, immunohistochemistry and/or western blot and attributed to acellular matrix of areas scored negative for KIT (CD117). RT-PCR results indicated that GIST samples did not express SCGF transcripts. The recently reported demonstration by Gundacker et al. 1 of the secretion of SCGF in mature pro-inflammatory dendritic cells would indicate a potential importance of SCGF in tissue inflammatory response. Accordingly, inflammatory infiltrates were detected in imatinib-affected areas and the CD68-positivity of the SCGF-positive and KIT-negative areas suggested previous infiltration of monocytes/macrophages into these regions. Thus, chronic inflammation subsequent to imatinib treatment may determine monocyte/macrophage recruitment in imatinib-damaged areas; these areas also feature prominent tumor-cell loss that is replaced by dense hyalinization and fibrosis. Our studies highlight a possible role of SCGFα in imatinib-induced changes of GIST structure, consistent with a therapeutic response.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>21943129</pmid><doi>10.1186/1479-5876-9-158</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1479-5876
ispartof Journal of translational medicine, 2011-09, Vol.9 (1), p.158-158, Article 158
issn 1479-5876
1479-5876
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_aebd56ac1997413d8dbbbc60c6042c04
source Publicly Available Content Database; PubMed Central(OpenAccess)
subjects Benzamides
Blotting, Western
Cell Line, Tumor
Electrophoresis, Polyacrylamide Gel
Gastrointestinal Stromal Tumors - drug therapy
Gastrointestinal Stromal Tumors - genetics
Gastrointestinal Stromal Tumors - metabolism
Gastrointestinal Stromal Tumors - pathology
Gene Expression Regulation, Neoplastic
Glycosylation
Hematopoietic Cell Growth Factors - genetics
Hematopoietic Cell Growth Factors - metabolism
Humans
Imatinib Mesylate
Immunohistochemistry
Lectins, C-Type - genetics
Lectins, C-Type - metabolism
Piperazines - therapeutic use
Proteomics - methods
Pyrimidines - therapeutic use
RNA, Messenger - genetics
RNA, Messenger - metabolism
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
Stromal Cells - metabolism
Stromal Cells - pathology
title Proteomic detection of a large amount of SCGFα in the stroma of GISTs after imatinib therapy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T00%3A05%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Proteomic%20detection%20of%20a%20large%20amount%20of%20SCGF%CE%B1%20in%20the%20stroma%20of%20GISTs%20after%20imatinib%20therapy&rft.jtitle=Journal%20of%20translational%20medicine&rft.au=Da%20Riva,%20Luca&rft.date=2011-09-23&rft.volume=9&rft.issue=1&rft.spage=158&rft.epage=158&rft.pages=158-158&rft.artnum=158&rft.issn=1479-5876&rft.eissn=1479-5876&rft_id=info:doi/10.1186/1479-5876-9-158&rft_dat=%3Cproquest_doaj_%3E898500939%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b517t-8cd06f72cda6ea5abad1092f0148d8fdef77ca57d52dc064c9471d80045962e63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=898500939&rft_id=info:pmid/21943129&rfr_iscdi=true